Industry B BioPharm International
David Berry to Close AAPS PharmSci 360 on Pharma Entrepreneurship
This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry B BioPharm International
This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
Industry
GEN
The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution. Closing this gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full value of its science. The post Overcoming Bottlenecks…
Industry
GEN
Researchers studying mice and human data identified a six gene signature, and developed a scorings system, that could help forecast acute myeloid leukemia patient survival, and potentially point to new therapeutic targets. The post Predicting Leukemia Survival May Be Aided by Six…
Regulatory P Pharmaceutical Executive
Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.
Agriculture
AgriBusiness Global
At the AgriBusiness Global Trade Summit, ag chem representatives from India and China debated which global powerhouse will define the future of ag input sourcing. The post The China-India Ag Input Relationship: Three Changes Defining the Ag Chem Landscape appeared first on AgriBu…
Agriculture
AgriBusiness Global
The free online tool designed to help companies and innovators pinpoint exactly where their product stands in the commercialization journey. The post AgriThority Launches Development Tool to Help Agricultural Innovators Gauge Commercialization Readiness appeared first on AgriBusi…
Clinical
Clinical Trials Arena
We bring you the highlights in endometrial and ovarian cancer from ESMO 2026, with readouts from MSD, AstraZeneca, Genmab and GSK. The post ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer appeared first on Clinical Trials Arena.
Research
BioPharma Dive
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.
Industry P pharmaphorum
Personal reflections on World ADC, San Diego Nicole.Raleigh Mon, 26/10/2026 - 16:05
Industry B BioPharm International
Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
Industry
European Biotechnology
Sweden's Spago Nanomedical will ask shareholders on Nov. 19 to approve delisting from Nasdaq First North, arguing that its listing obstructs financing on acceptable terms for Phase 2a development of its Tumorad radiopharmaceutical in head and neck cancer. The post Spago Nanomedic…
Industry
BioPharma Dive
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
Clinical A Applied Clinical Trials
Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restrai…
Industry
Pharmaceutical Technology
In the Phase III SANOVO trial, Orpathys extended PFS to 24.8 months in IHC 3+ NSCLC, but tolerability may weigh as heavily as efficacy.
Industry B BioPharm International
Full Phase 3 TroFuse-005 data presented at ESMO 2026 show the TROP2-directed ADC sacituzumab tirumotecan cut the risk of death by 32% vs chemotherapy, and an FDA decision is expected by June 2027.
Clinical B BioPharm International
A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.
Industry
STAT Biotech
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.
Industry B BioTechniques
A key metabolic pathway has been identified that provides a deeper insight into the link between moderately cold temperatures and enhanced longevity. We’ve heard it before: there’s a link between cold temperatures and longevity, but we know very little about the actual mechanism…
Industry
Clinical Trials Arena
In the Phase III OptiTROP-Lung04 trial, sac-TMT extended median OS to 25.9 months in EGFR-mutated NSCLC. The post ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD appeared first on Clinical Trials Arena.
Software S SecureBio
How capable are general purpose AI models at reproducing a published biological AI tool? Our latest benchmark helps us assess this capability on commonly used biological and chemical AI tools.
Clinical P pharmaphorum
ESMO26: Taiho Oncology on improving the lives of patients with cancer, their families, and their caregivers Nicole.Raleigh Mon, 26/10/2026 - 15:18
Clinical B BioPharm International
BioNTech and DualityBio's HER2-directed ADC modestly improved progression-free survival over chemotherapy in DYNASTY-Breast02, but higher interstitial lung disease rates and an established competitor limit its potential in this setting.
Clinical
Inside Precision Medicine
UBT251, the triple hormone-receptor agonist developed by United Biotechnology and licensed by Novo Nordisk, has achieved good results in people with type 2 diabetes at Phase II. The post Novo’s Answer to Retatrutide Does Well at Phase II in Type 2 Diabetes appeared first on Insid…
Industry
Inside Precision Medicine
A miniature implant can release drugs over time and improve their distribution through brain tissue using ultrasound waves. The post Brain Implant Could Prevent Glioblastoma Relapse with Ultrasound Drug Delivery appeared first on Inside Precision Medicine.
Industry P Pharmafile
Researchers at Manchester Metropolitan University are investigating whether regular hot-water immersion can improve mobility and relieve pain in people with peripheral artery disease (PAD), with funding from the British Heart Foundation. The HEATPAD study aims to recruit 70 peopl…
Software P Pharmaceutical Commerce
Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch and regulatory work.
Research
Drug Delivery Business
Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor. The first-in-human trial of its Freedom system will evaluate a one-year, under-the-skin sensor that links directly with the user’s smartpho…
Software
European Biotechnology
AI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its impact is often overstated. Evidenze’s Raphaela Schnurbus explains where AI is delivering measurable value today, where human expertise remains essential and…
Manufacturing B BioProcess International
The rapid growth of ADCs, HPAPIs, and other next-generation therapies is creating new challenges for manufacturers and facility designers alike. As pipelines diversify and new conjugation approaches emerge, facilities designed around today’s processes must be prepared for evolvin…
Industry
MedTech Dive
At AdvaMed’s The MedTech Conference, CEOs from top medical device companies shared how they navigate difficult times, inflation and new technologies.
Regulatory P pharmaphorum
Bayer gets first approval for stroke drug asundexian Phil.Taylor Mon, 26/10/2026 - 14:11
Clinical P Pharmaceutical Executive
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Industry
European Biotechnology
Inspired by technology and insights gleaned from cancer research, Europe is leading the quest for a new generation of therapies in immunology and inflammation. Immunotherapy has revolutionised cancer therapy and become standard of care in many areas of oncology but it has also…
Manufacturing P Pharmaceutical Commerce
At LogiPharma USA 2026, Freehand's Nitin Jayakrishnan explains why AI and the people supply chain will shape pharma supply strategy.
Industry
Labiotech
Delve into Novavax's pipeline and strategy as the company shifts to a partnership-driven model post-COVID-19. The post Novavax’s new strategy: Betting its future on partnerships appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplica…
Industry P PLOS Biology
by Hao Song, Tingyu Shi, Meijie Yang, Xiaoyan Liu, Zhuoqing Li, Pu Shi, Yu Wu, Bassem Allam, Andrew Jeffs, Bradley Skelton, Tao Zhang Forecasts of whether marine species can evolve fast enough to survive climate change rely largely on single-stage tolerance assays, tacitly assumi…
Industry P PLOS Biology
by Lavanya Gupta, Sinem Agilkaya, Kim Susann Keller, Ebru Ercan-Herbst The central problem when delivering drugs to the brain is no longer crossing the blood–brain barrier, but delivering therapeutics to the right cells, in the right regions to target neurodegeneration, within a…
Industry
BioPharma Dive
A patient who received Bristol Myers’ zola-cell died 44 days later. Elswehere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
Industry
STAT Biotech
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer
Industry
STAT Biotech
Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.